GALECTO INC (GLTO)

US36322Q1076 - Common Stock

4.7  +0.04 (+0.86%)

Fundamental Rating

2

Overall GLTO gets a fundamental rating of 2 out of 10. We evaluated GLTO against 568 industry peers in the Biotechnology industry. GLTO has a great financial health rating, but its profitability evaluates not so good. GLTO has a expensive valuation and it also scores bad on growth.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

GLTO had negative earnings in the past year.
GLTO had a negative operating cash flow in the past year.
In the past 5 years GLTO always reported negative net income.
In the past 5 years GLTO always reported negative operating cash flow.

1.2 Ratios

GLTO has a worse Return On Assets (-90.58%) than 72.74% of its industry peers.
GLTO has a Return On Equity (-101.14%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -90.58%
ROE -101.14%
ROIC N/A
ROA(3y)-75.62%
ROA(5y)-64.3%
ROE(3y)-87.49%
ROE(5y)-74.05%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

GLTO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

7

2. Health

2.1 Basic Checks

GLTO has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, GLTO has less shares outstanding
There is no outstanding debt for GLTO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -16.59, we must say that GLTO is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of GLTO (-16.59) is worse than 83.72% of its industry peers.
GLTO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -16.59
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

GLTO has a Current Ratio of 8.68. This indicates that GLTO is financially healthy and has no problem in meeting its short term obligations.
GLTO's Current ratio of 8.68 is fine compared to the rest of the industry. GLTO outperforms 75.75% of its industry peers.
GLTO has a Quick Ratio of 8.68. This indicates that GLTO is financially healthy and has no problem in meeting its short term obligations.
GLTO's Quick ratio of 8.68 is fine compared to the rest of the industry. GLTO outperforms 75.75% of its industry peers.
Industry RankSector Rank
Current Ratio 8.68
Quick Ratio 8.68

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 58.44% over the past year.
EPS 1Y (TTM)58.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.8%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, GLTO will show a decrease in Earnings Per Share. The EPS will decrease by -0.54% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y38.74%
EPS Next 2Y21.33%
EPS Next 3Y7.21%
EPS Next 5Y-0.54%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GLTO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GLTO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.33%
EPS Next 3Y7.21%

More info and screens

0

5. Dividend

5.1 Amount

GLTO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GALECTO INC

NASDAQ:GLTO (12/20/2024, 8:14:59 PM)

4.7

+0.04 (+0.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-01 2024-11-01/bmo
Earnings (Next)N/A N/A
Inst Owners17.69%
Inst Owner Change-96.81%
Ins Owners3.6%
Ins Owner Change0%
Market Cap6.20M
Analysts85.71
Price Target10.2 (117.02%)
Short Float %1.59%
Short Ratio0.91
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)34.58%
Min EPS beat(2)18.96%
Max EPS beat(2)50.2%
EPS beat(4)4
Avg EPS beat(4)36.28%
Min EPS beat(4)18.96%
Max EPS beat(4)52.18%
EPS beat(8)8
Avg EPS beat(8)29.91%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)11.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1415.56%
EPS NY rev (1m)0%
EPS NY rev (3m)6.72%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.3
P/tB 0.3
EV/EBITDA N/A
EPS(TTM)-18.39
EYN/A
EPS(NY)-19.27
Fwd EYN/A
FCF(TTM)-19.06
FCFYN/A
OCF(TTM)-19.06
OCFYN/A
SpS0
BVpS15.86
TBVpS15.86
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -90.58%
ROE -101.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-75.62%
ROA(5y)-64.3%
ROE(3y)-87.49%
ROE(5y)-74.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.68
Quick Ratio 8.68
Altman-Z -16.59
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)533.33%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.8%
EPS Next Y38.74%
EPS Next 2Y21.33%
EPS Next 3Y7.21%
EPS Next 5Y-0.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y54.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-30.35%
EBIT Next 3Y-18.73%
EBIT Next 5YN/A
FCF growth 1Y49.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y48.98%
OCF growth 3YN/A
OCF growth 5YN/A